Targeting protein kinases for anti-glioma treatment

Abstract

The genetic alterations related to many kinases are responsible for the formation of glial tumours. In addition it is the cell kinases that keep the cancerous signalling machinery in motion, thus enabling tumour cell growth, motility and invasion. Kinase inhibitors may have a potential to surpass the classical oncolytic treatment for gliomas. However, overcoming drug resistance mechanisms and limited blood-brain barrier (BBB) permeability are the remaining daunting issues. Latest research explores novel kinase inhibitors, yielding several promising results, including those from CK2 inhibition studies, as well as the possibility of relabelling the inhibitors previously approved for tumours other than glial tumours.

Ca2+-Dependent Effects of the Selenium-Sorafenib Nanocomplex on Glioblastoma Cells and Astrocytes of the Cerebral Cortex: Anticancer Agent and Cytoprotector

“…Protein kinases regulate almost all intracellular processes and, as a result, determine cell proliferation, differentiation, survival, and death of both normal and cancer cells [35,36]. Following a 24-h incubation of glioblastoma cells with 3 µg/mL So, either there was no change in the expression of genes encoding kinases (VEGFR, RAS,RAF, MLKL, mTOR, and PI3K), or an increase in their expression was observed-RIPK1, MAPK1, MAPK3, FLT3, and KIT (Figure 10A-black columns).…”